Rioux-Labrecque V, Cossette M, Rufiange M, Bilodeau D, Guertin MC, Tardif JC. Supplementation with a beta-glucan tablet has no effect on hyperlipidemia: a randomized, placebo-controlled clinical trial.
Am J Clin Nutr 2023:S0002-9165(23)46841-4. [PMID:
37054888 DOI:
10.1016/j.ajcnut.2023.04.012]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Revised: 03/24/2023] [Accepted: 04/10/2023] [Indexed: 04/15/2023] Open
Abstract
BACKGROUND
Clinical evidence has suggested that the oat soluble fiber β-glucan might have lipid-lowering effects.
OBJECTIVE
The present clinical trial was conducted to evaluate the efficacy and safety of high-medium molecular weight β-glucan on serum low-density lipoprotein cholesterol (LDL-C) and other lipid subfractions in subjects with hyperlipidemia.
METHODS
A randomized double-blind trial was performed to assess the efficacy and safety of β-glucan supplementation in reducing lipid levels. Subjects with LDL-C above 3.37 mmol/L when treated or not with a statin were randomly assigned to receive one of three daily doses of a tableted formulation of β-glucan (1.5, 3 or 6 grams) or placebo. The primary efficacy endpoint was the change from baseline to 12 weeks in LDL-C. Secondary endpoints of lipid sub-fractions and safety were also assessed.
RESULTS
A total of 263 subjects were enrolled; 66 subjects were assigned to each of the 3 β-glucan groups and 65 subjects to the placebo group. The mean change from baseline to 12 weeks in serum LDL-C was 0.08, 0.11 and -0.04 mmol/L in the three β-glucan groups (P=0.23, 0.18 and 0.72 vs. placebo group, respectively) and -0.10 mmol/L in the placebo group. The changes in total cholesterol, small LDL-C subclass particle concentration, non-high-density lipoprotein cholesterol, apolipoprotein B, very low-density lipoprotein cholesterol and high sensitivity C-reactive protein were also not significant in the β-glucan groups when compared to placebo. Gastrointestinal adverse events were reported in 23.4, 34.8 and 66.7% of patients in the β-glucan groups and in 36.9% of patients in the placebo group (P<0.0001 for the overall comparison across the four groups).
CONCLUSIONS
In subjects with LDL-C above 3.37 mmol/L, a tablet formulation of β-glucan was not effective in reducing LDL-C concentration or other lipid sub-fractions when compared to placebo.
CLINICALTRIALS
GOV IDENTIFIER
NCT03857256.
Collapse